<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P09708565A0000 The purpose of this article is to discuss the factors involved in the selection of antibodies, radionuclides and labeling methods in the development of radioimmunotherapy (RIT) for non-Hodgkin's lymphoma (NHL) from a single clinical study site through multicenter trials and commercialization."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="308" language="x-unspecified"/></CAS>